Additional information
Specialty | |
---|---|
Dosage | |
Form | |
Presentation | |
Primary packaging | |
Specification | |
DCI | |
Classement VEIC | |
Therapeutic class | |
Sub Class | |
Laboratory | |
CHART | |
The duration of the conversation | |
Generic / Princeps | |
AMM | |
Date AMM | |
Range |
Prevention of cerebrovascular accidents (CVA) and systemic embolisms in adult patients with non-valvular atrial fibrillation and presenting one or more risk factors (s), such as congestive heart failure, high blood pressure, age> = 75 years, diabetes, history of stroke or transient ischemic attack. Treatment of deep vein thrombosis (DVT) and pulmonary embolism, and prevention of recurrence in the form of DVT and PE in adults.
Specialty | |
---|---|
Dosage | |
Form | |
Presentation | |
Primary packaging | |
Specification | |
DCI | |
Classement VEIC | |
Therapeutic class | |
Sub Class | |
Laboratory | |
CHART | |
The duration of the conversation | |
Generic / Princeps | |
AMM | |
Date AMM | |
Range |